Economic evaluation of the vaccination program against seasonal and pandemic A/H1N1 influenza among customs officers in Greece
- PMID: 23195436
- DOI: 10.1016/j.healthpol.2012.10.013
Economic evaluation of the vaccination program against seasonal and pandemic A/H1N1 influenza among customs officers in Greece
Abstract
Introduction: Health policies from many countries recommend influenza vaccination of "high-priority" professional groups, including customs officers. Our aim was to estimate the economic impact of the vaccination program against influenza among customs officers in Greece during the 2009/2010 period.
Materials and methods: We developed a decision analytical computational simulation model including dynamic transmission elements that estimated the economic impact of various scenarios with different attack rates, symptomatic percentages and vaccination participation among customs officers. We also assessed in real-time the economic impact of the national 2009/2010 campaign against seasonal and pandemic A/H1N1 influenza.
Results: Implementing a seasonal and pandemic A/H1N1 influenza vaccination program among customs officers in Greece with a participation rate of 30%, influenza vaccination was not cost-saving in any of the studied influenza scenarios. When the participation rate reached 100%, the program was cost-saving, when the influenza attack rate was 30% and the symptomatic rate 65%. The real-time estimated mean net cost-benefit value in 2009/2010 period was -7.3 euros/custom officer.
Conclusions: With different clinical scenarios, providing a vaccination program against seasonal and pandemic A/H1N1 influenza can incur a substantial net benefit for customs offices. However, the size of the benefit strongly depends upon the attack rate of influenza, the symptomatic rate as well as the participation rate of the customs officers in the program.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Swine influenza and vaccines: an alternative approach for decision making about pandemic prevention.Eur J Public Health. 2013 Aug;23(4):669-73. doi: 10.1093/eurpub/ckt004. Epub 2013 Mar 26. Eur J Public Health. 2013. PMID: 23531523
-
Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation.Vaccine. 2010 Mar 11;28(12):2370-84. doi: 10.1016/j.vaccine.2010.01.002. Epub 2010 Jan 21. Vaccine. 2010. PMID: 20096762
-
Assessing households' willingness to pay for an immediate pandemic influenza vaccination programme.Scand J Public Health. 2012 Jul;40(5):412-7. doi: 10.1177/1403494812453884. Epub 2012 Jul 13. Scand J Public Health. 2012. PMID: 22798286
-
Uptake of pandemic influenza (H1N1)-2009 vaccines in Brazil, 2010.Vaccine. 2012 Jul 6;30(32):4744-51. doi: 10.1016/j.vaccine.2012.05.007. Epub 2012 May 18. Vaccine. 2012. PMID: 22609010 Review.
-
The 2009 influenza A virus subtype H1N1 pandemic, a glance from Greece.Infez Med. 2016 Dec 1;24(4):259-264. Infez Med. 2016. PMID: 28011959 Review.
Cited by
-
Influenza Vaccination Assessment according to a Value-Based Health Care Approach.Vaccines (Basel). 2022 Oct 8;10(10):1675. doi: 10.3390/vaccines10101675. Vaccines (Basel). 2022. PMID: 36298540 Free PMC article. Review.
-
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.Pharmacoeconomics. 2016 Sep;34(9):833-45. doi: 10.1007/s40273-016-0410-3. Pharmacoeconomics. 2016. PMID: 27129572 Free PMC article.
-
Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature.Eur J Health Econ. 2020 Dec;21(9):1329-1350. doi: 10.1007/s10198-020-01218-4. Epub 2020 Aug 13. Eur J Health Econ. 2020. PMID: 32789780 Free PMC article. Review.
-
Customs officers in relation to viral infections, tuberculosis, psittacosis and environmental health risk.Exp Ther Med. 2019 Feb;17(2):1149-1153. doi: 10.3892/etm.2018.7077. Epub 2018 Dec 10. Exp Ther Med. 2019. PMID: 30679987 Free PMC article. Review.
-
[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0].J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec. J Prev Med Hyg. 2023. PMID: 37034835 Free PMC article. Italian. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical